Sunil Sharma

5.2k total citations
71 papers, 1.6k citations indexed

About

Sunil Sharma is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sunil Sharma has authored 71 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 22 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sunil Sharma's work include Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Sunil Sharma is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Cancer Treatment and Pharmacology (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Sunil Sharma collaborates with scholars based in United States, India and Switzerland. Sunil Sharma's co-authors include Leonard B. Saltz, David H. Ilson, Eileen M. O’Reilly, David P. Kelsen, Mark G. Kris, Nancy E. Kemeny, A. R. Imondi, Dorothy A. White, Gary K. Schwartz and Sridhar Mani and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sunil Sharma

68 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sunil Sharma United States 22 643 538 409 214 151 71 1.6k
Lucille Leong United States 23 691 1.1× 502 0.9× 265 0.6× 270 1.3× 119 0.8× 74 1.6k
Annamaria Catino Italy 22 476 0.7× 329 0.6× 453 1.1× 217 1.0× 100 0.7× 114 1.5k
Junichi Sakamoto Japan 24 735 1.1× 586 1.1× 684 1.7× 389 1.8× 142 0.9× 98 2.2k
Hyeong Su Kim South Korea 24 650 1.0× 437 0.8× 615 1.5× 308 1.4× 137 0.9× 117 1.7k
Gennaro Daniele Italy 24 970 1.5× 559 1.0× 577 1.4× 179 0.8× 101 0.7× 100 1.9k
David Jamieson United Kingdom 20 731 1.1× 502 0.9× 383 0.9× 75 0.4× 161 1.1× 42 1.5k
Bristi Basu United Kingdom 21 817 1.3× 638 1.2× 249 0.6× 126 0.6× 138 0.9× 85 1.5k
Angelica Petrillo Italy 19 551 0.9× 233 0.4× 350 0.9× 237 1.1× 114 0.8× 68 1.1k
Sérgio Rizzo Italy 25 1.0k 1.6× 559 1.0× 635 1.6× 124 0.6× 230 1.5× 74 2.0k

Countries citing papers authored by Sunil Sharma

Since Specialization
Citations

This map shows the geographic impact of Sunil Sharma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunil Sharma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunil Sharma more than expected).

Fields of papers citing papers by Sunil Sharma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunil Sharma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunil Sharma. The network helps show where Sunil Sharma may publish in the future.

Co-authorship network of co-authors of Sunil Sharma

This figure shows the co-authorship network connecting the top 25 collaborators of Sunil Sharma. A scholar is included among the top collaborators of Sunil Sharma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunil Sharma. Sunil Sharma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Suchomel, Julia, Doreen Anders, Rucha Sane, et al.. (2024). Impact of P‐gp inhibition on systemic exposure of pralsetinib and dosing considerations. Clinical and Translational Science. 17(6). e13818–e13818. 1 indexed citations
3.
Saha, Lekha, et al.. (2024). Role of berberine nanoformulation in epilepsy: A novel therapeutic strategy. Epilepsy Research. 205. 107419–107419. 1 indexed citations
4.
Birdwell, Christine, Warren Fiskus, Tapan M. Kadia, et al.. (2023). Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia. 38(3). 545–556. 5 indexed citations
5.
Sattler, Martin, Isa Mambetsariev, Nagarajan Vaidehi, et al.. (2023). A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine. Journal of Clinical Medicine. 12(5). 1936–1936. 9 indexed citations
6.
Sommerhalder, David, Marcus Smith Noel, Scott Boiko, et al.. (2023). 751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor. SHILAP Revista de lepidopterología. A847–A847. 3 indexed citations
7.
8.
Soldi, Raffaella, Tithi Ghosh, Hariprasad Vankayalapati, et al.. (2021). The Small Molecule BC-2059 Inhibits Wingless/Integrated (Wnt)-Dependent Gene Transcription in Cancer through Disruption of the Transducin β-Like 1-β-Catenin Protein Complex. Journal of Pharmacology and Experimental Therapeutics. 378(2). 77–86. 11 indexed citations
9.
Griffiths, Jason I., Pierre Wallet, Lance Pflieger, et al.. (2020). Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy. Proceedings of the National Academy of Sciences. 117(27). 16072–16082. 67 indexed citations
10.
Soldi, Raffaella, Tithi Ghosh, Kevin Drenner, et al.. (2020). The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer. PLoS ONE. 15(7). e0235705–e0235705. 60 indexed citations
11.
Vasudeva, Neeru, et al.. (2019). Kidney disorders and management through herbs: A Review. The Journal of Phytopharmacology. 8(1). 21–27. 7 indexed citations
12.
Pishas, Kathleen I., Christina D. Drenberg, Cenny Taslim, et al.. (2018). Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics. 17(9). 1902–1916. 42 indexed citations
13.
Gilcrease, Glynn Weldon, David D. Stenehjem, Mark Wade, et al.. (2018). Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer. Investigational New Drugs. 37(3). 482–489. 17 indexed citations
14.
Machiels, Jean Pascal, Arthur P. Staddon, Charles E. Phelps, et al.. (2014). Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies. Cancer Chemotherapy and Pharmacology. 74(4). 729–737. 5 indexed citations
15.
Sharma, Sunil, Elisabeth G.E. de Vries, Jeffrey R. Infante, et al.. (2013). Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Investigational New Drugs. 32(1). 135–144. 39 indexed citations
16.
Hamberg, Paul, Margaret M. Woo, Lin‐Chi Chen, et al.. (2011). Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor. Cancer Chemotherapy and Pharmacology. 68(3). 805–813. 42 indexed citations
17.
18.
Kemeny, Nancy E., W P Tong, Mithat Gönen, et al.. (2002). Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. Annals of Oncology. 13(9). 1490–1496. 17 indexed citations
19.
Nash, Garrett M., Leonard B. Saltz, Nancy E. Kemeny, et al.. (2002). Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. Annals of Surgical Oncology. 9(10). 954–960. 44 indexed citations
20.
Soda, Hiroshi, et al.. (1999). Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors. Anti-Cancer Drugs. 10(1). 97–102. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lucille Leong Breakdown of academic impact, for papers by Annamaria Catino Breakdown of academic impact, for papers by Junichi Sakamoto Breakdown of academic impact, for papers by Hyeong Su Kim Breakdown of academic impact, for papers by Gennaro Daniele Breakdown of academic impact, for papers by David Jamieson Breakdown of academic impact, for papers by Bristi Basu Breakdown of academic impact, for papers by Angelica Petrillo Breakdown of academic impact, for papers by Sérgio Rizzo
Rankless by CCL
2026